Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Active negotiation
Manufacturer:
Galderma Canada Inc.
Indication:
For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.
Last updated:
March 12, 2026
Status:
Under consideration for negotiation
Manufacturer:
Theratechnologies Inc.
Indication:
As an adjunct to diet for the treatment of adults with familial chylomicronemia syndrome (FCS) to reduce triglyceride levels.
Last updated:
March 12, 2026
Enhertu (trastuzumab deruxtecan)
Status:
Active negotiation
Manufacturer:
AstraZeneca Canada Inc.
Indication:
For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.
Last updated:
March 12, 2026
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Multiple Indications
Last updated:
March 9, 2026
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated:
March 6, 2026